Advanced glycation endproducts in the pathogenesis of chronic kidney disease

Naila Rabbani and Paul J. Thornalley

Warwick Medical School, Clinical Sciences Research Laboratories, University of Warwick, University Hospital, Coventry CV2 2DX, U.K.

Correspondence to: Professor Paul J Thornalley, Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, University Hospital, Clifford Bridge Road, Coventry CV2 2DX, U.K. Email: P.J.Thornalley@warwick.ac.uk Tel +44 7696 8594 Fax +44 24 7696 8653

Word count: abstract 249; main text 3952.

Abstract

Advanced glycation endproducts (AGEs) are stable post-translational modifications of proteins formed by the spontaneous reaction with glucose and related metabolites. Important AGEs quantitatively are methylglyoxal (MG)-derived hydroimidazolone MG-H1, N_ε-carboxymethyl-lysine (CML) and glucosepane. They contribute to the development of chronic kidney disease (CKD). Cellular proteolysis of AGE-modified proteins forms AGE free adducts, glycated amino acids, which are cleared by the kidneys and excreted in urine. Dietary AGEs mainly supplement the endogenous flux of AGE free adduct formation. AGE free adducts accumulate markedly in plasma with decline in glomerular filtration rate. A key precursor of AGEs is the dicarbonyl metabolite, MG, which is metabolised by glyoxalase 1 (Glo1) of the cytoplasmic glyoxalase system. Proteins susceptible to MG modification are called collectively the "dicarbonyl proteome". Abnormal increase of MG "dicarbonyl stress" and is a characteristic of CKD, driven by down regulation of renal Glo1, increasing flux of MG-H1 formation. Protein inactivation and dysfunction linked to the dicarbonyl proteome contributes to CKD development. The receptor for AGEs, RAGE, is important in development of CKD but its interaction with AGEs *in vivo* remains enigmatic; other ligands and ternary complexation may be influential. Prevention of diabetic kidney disease (DKD) by overexpression of Glo1 in transgenic animal models has stimulated the development of small molecule inducers of Glo1 expression, "Glo1 inducers", to prevent AGE formation. *trans*-Resveratrol-hesperetin combination therapy is a Glo1 inducer. In clinical trial it gave a profound improvement in insulin resistance and vascular inflammation. It may find future therapeutic application for treatment of DKD.

Advanced glycation endproducts

Advanced glycation endproducts (AGEs) are a group of compounds formed by the non-enzymatic reaction of reducing sugars and related metabolites with proteins and amino acids. The process is called glycation or the Maillard reaction. Major precursors of AGEs *in vivo* are the early-stage glycation adduct, N_ε-fructosyl-lysine (FL), and dicarbonyl metabolites methylglyoxal (MG), glyoxal and 3-deoxyglucosone (3-DG).[1] Major AGEs quantitatively are MG-derived hydroimidazolone MG-H1 and FL-derived N_ε-carboxymethyl-lysine (CML) and the crosslink glucosepane - Figure 1. AGEs are formed as glycated amino acid residues of proteins which are conventionally called "AGE residues" of proteins, although they are often called "protein-bound AGEs" in renal research. AGE-modified proteins are degraded to related glycated amino acids, called AGE free adducts. AGEs are also formed from glucose osmolyte, MG and other glucose degradation product dicarbonyls absorbed from thermally processed dialysis fluids in renal replacement therapy. AGEs may also be absorbed from glycated proteins in food, mainly as AGE free adducts. AGEs may be quantified robustly by stable isotopic dilution analysis liquid chromatography-tandem mass

spectrometry (LC-MS/MS).[1] AGEs represent relatively long-lived and potentially damaging post-translational modification of proteins. They are mostly damaging through modification of functional domains of proteins, producing protein inactivation or dysfunction.

Herein we review evidence of protein-derived AGEs. There are also AGEs formed by MG and glyoxal modification of nucleotides and basic phospholipids, phosphatidylethanolamine and phosphatidylserine.[2, 3] These have been little-studied in chronic kidney disease (CKD)[4] and so the coverage below focusses on protein-derived AGEs.

The formation of AGEs is suppressed by enzymatic metabolism of the precursor glycating agents or glycation adduct, FL. MG and glyoxal are metabolised mainly by the cytoplasmic glyoxalase system. The glyoxalase system consists of 2 enzymes, glyoxalase 1 (Glo1) and glyoxalase 2 and a catalytic amount of reduced glutathione (GSH). Glo1 catalyses the GSH-dependent metabolism of MG to S-D-lactoylglutathione, and glyoxalase 2 catalyses the hydrolysis of S-D-lactoylglutathione to D-lactate, reforming GSH consumed in the Glo1 catalysed step[5] – Figure 2. 3-DG and likely also 3,4-dideoxyglucosone-**3**-ene (3,4-DGE) found in thermally processed peritoneal dialysis (PD) fluids with glucose osmolyte are metabolised by aldoketo reductases (AKRs) and aldehyde dehydrogenases. The kidney has a very high activity of aldose reductase, *ca.* 2% total protein, in the inner medulla which primarily reduces glucose to sorbitol to counter high extracellular osmotic pressure.[6] Steady-state levels of FL residues are suppressed by enzymatic metabolism by fructosamine-3-phosphokinase, resulting in de-glycation of precursor lysine residues.[1]

Dicarbonyl stress
Dicarbonyl stress is the abnormal accumulation of MG and related dicarbonyl compounds, leading to increased AGE formation and related cell and tissue dysfunction. Dicarbonyl stress is a driver of CKD development – as evidenced by development of nephropathy in Glo1 deficient mice.[7] Dicarbonyl stress may also be consequence of renal failure, as evidenced by dicarbonyl stress with loss of clearance in bilateral nephrectomised rats.[8] Dicarbonyl stress occurs in patients with CKD,[5] including accumulation of MG without increase in D-lactate in non-diabetic subjects.[9] D-Lactate is a marker of flux of formation of MG.[10] This suggests the driver of dicarbonyl stress in CKD is down regulation of Glo1 rather than increased formation of MG in non-diabetic subjects. Decreased urinary excretion of MG is not a major contributing factor since little MG is excreted – although this may be more important for 3-DG.[10] Down regulation of Glo1 in the kidney is a common feature of experimental diabetic nephropathy and diabetic kidney disease (DKD). It may be driven by decreased Glo1 expression in response to hypoxia-inducible factor-1α and inflammatory signalling conflicting with transcription factor Nrf2, and by increased proteolysis. Overexpression of Glo1 prevented renal senescence[11] and development of diabetic nephropathy[7, 12] – the latter even when only in endothelial and tubular epithelial cells.[7] This suggests reversing renal down regulation of Glo1 may provide a new route to therapy.[10]

The flux of MG formation in a healthy adult human subject is *ca.* 3 mmol MG per 24 h and >99% is normally metabolised enzymatically. MG concentration of PD fluids, 2 – 7 µM, is therefore not a major increment to MG exposure. For 3-DG, the flux of formation is *ca.* 0.13 mmol 3-DG per 24 h and *ca.* 90% is normally metabolised enzymatically with *ca.* 10% excreted. PD fluids containing 100 – 400 µM 3-DG increase exposure to 3-DG markedly, although 3-DG has *ca.* 200-fold lower reactivity that MG.[5, 10]

Accumulation of AGEs in renal failure – the profound increase of AGE free adducts
AGE free adducts are the major form by which AGEs are eliminated from the body. Decreased clearance in CKD markedly influences the plasma concentrations of AGE free adducts.[8, 13] The increase of AGE free adducts in clinical renal failure, studied in patients

receiving hemodialysis (HD) and PD renal replacement therapy was 4 - 40 fold whereas the increase in AGE residues of plasma protein was 2 – 5 fold.[13] Drivers of AGE free adduct accumulation are increased flux of formation of AGEs and decreased clearance. The flux of formation of AGEs is indicated by the total excretion of AGE free adducts in dialysate and urine. In PD patients, flux of AGE formation was increased markedly with respect to healthy controls: 9-fold for MG-H1 and 2-fold for CML, pentosidine and 3-DG-derived hydroimidazolones 3DG-H. The flux of excretion of MG-H1 free adduct in PD patients was 4 – 713 fold higher than of other AGEs, indicating MG-H1 is a dominant AGE in renal failure.[13]

AGE residue contents of plasma protein have been studied as biomarkers of mortality risk in renal failure with contrary outcomes or low marginal increased relative risk.[14, 15] Plasma protein AGEs, such as MG-H1 and 3DG-H, may be increased by dicarbonyl stress;[13] CML and glucosepane may be increased by elevated FL residue precursor and/or decreased FL metabolism;[16-18] and pentosidine residue content may be increased by elevated pentosephosphate pathway activity providing increased level of the pentose precursor.[19] AGE residue content of plasma protein is also influenced by decreased residence time of albumin in the vascular compartment by albuminuria,[20] increased transcapillary escape rate – influenced by hypertension and atherosclerosis;[21] and also by decreased albumin synthesis and catabolism.[22] These confounders suggest AGE residue content of plasma protein has a complex relationship with clinical outcomes in CKD.

An indication of increased AGE formation in the kidney may be gained by measuring total body flux of formation of AGEs, or surrogate measures thereof: such as urinary or dialysate flux of AGE free adducts, plasma AGE free adduct concentration corrected for decline in glomerular filtration rate (GFR) in CKD stages G1 – G4, and plasma AGE free adduct concentration immediately prior to a dialysis session in HD patients or dialysis fluid exchange in PD patients. Correction may be made for contributions from food AGEs – see below.

Measurement of AGEs for assessment of risk of development and progression of CKD

In a large cross-sectional study, increased serum CML measured by a competitive immunoassay was associated with CKD and negatively associated with GFR.[23] The immunoassay used measured both serum protein CML residues and CML free adduct concurrently.[24] CML free adduct is most sensitive to loss of renal clearance[8] and so such immunoassay formats may be reflecting accumulation of CML free adduct. Total plasma AGEs, the sum protein residues and free adducts, the sum of AGE residues of protein and AGE free adduct, of selected types are determined by analysis of acid hydrolysates of plasma. Total plasma CML and CEL were increased in patients with type 1 diabetes and decreased GFR, compared to those with normal GFR, and were linked to markers of endothelial cell dysfunction - von Willebrand factor, soluble vascular cellular adhesion molecule-1 (sVCAM1), and soluble thrombomodulin – independent of GFR.[25] Total plasma pentosidine was a risk predictor of mortality in CKD after adjusting for all confounders.[26] In recent studies of AGEs and related analysis of skin collagen in patients with type 1 diabetes, an analyte panel of glucosepane, MG-H1, CML, N_ε(1-carboxyethyl)lysine (CEL), glyoxal-derived hydroimidazolone (G-H1), pentosidine, furosine, collagen fluorescence, skin collagen acid solubility and pepsin digestibility were linked to risk of progression of diabetic nephropathy; with the FL-linked analyte furosine being the strongest predictor.[27] In contrast, CML residue content of plasma protein was not linked to the risk of developing diabetic nephropathy.[28] Plasma MG-H1 free adduct concentration was an independent risk predictor for progression of DKD.[29] Low molecular weight AGE fluorophore measurement was a mortality predictor in HD patients.[30]

Skin autofluorescence (SAF) has been proposed as an non-invasive measure linked to the dermal content of AGEs.[31] Spectrofluorometric analysis and scanning confocal microscopy and multi-photon excitation microscopy found that major contributions to SAF are from NAD(P)H, flavin adenine dinucleotide and porphyrins.[32, 33] There are also contributions from the oxidative fluorophore, N-formylkynurenine, and trace fluorescent AGEs such as pentosidine and others.[31] Weaknesses of this approach are that SAF has important non-AGE contributions and the major quantitative AGEs in CKD, MG-H1 and CML, are not fluorescent. Change in SAF is likely reflecting a combination of metabolic dysfunction and protein-derived fluorophores in CKD. In assessment of risk of progression of CKD, an optimum cut-off level of SAF gave sensitivity 0.74 and specificity of 0.73 for CKD progression[34] and SAF was also linked to mortality risk in renal failure.[35]

Revisited and new and concepts in AGE-related pathogenesis
The AGE receptor hypothesis revisited
It was proposed that AGE-modified proteins bind specifically to cell surface receptors to activate cell dysfunction. This was questioned and considered limited to proteins structurally-damaged and/or glycated to high, supraphysiological extents prepared *in vitro*.[36, 37] An AGE receptor found influential on the development of experimental diabetic nephropathy and DKD is the receptor for advanced glycation endproducts, RAGE. Transgenic mice overexpressing RAGE showed glomerular hypertrophy, increased albuminuria, mesangial expansion, advanced glomerulosclerosis, and increased serum creatinine compared to non-transgenic diabetic littermates.[38] RAGE-deficient mice show decreased albuminuria, hyperfiltration and glomerulosclerosis compared with diabetic wild-type controls.[39] RAGE expression is increased in peripheral blood monocytes in clinical CKD.[40]

The use of albumin highly glycated by AGEs, dissimilar from albumin which is minimally modified by AGEs *in vivo*, has made studies of the metabolism and functional responses induced by AGE-modified proteins by RAGE and other putative AGE receptors difficult to understand and interpret. Typical glucose-derived AGE-modified albumin prepared *in vitro* had *ca.* 7,000 Da mass increment of glycation adducts, *ca.* 40 – 50 molar equivalents of modification, markedly increase negative charge, bound to RAGE and had rapid clearance by scavenger receptor-mediated removal from circulation in the liver.[41-43] In contrast, albumin *in vivo* typically has <1% modification by one AGE residue, a mass increment of <200 Da (mostly due to early glycation adduct FL), little change in charge, may not always bind RAGE and shows little extraction from circulation in the liver.[13, 22, 41, 44-46] Mathematical modelling of glycation kinetics and protein turnover supports experimental findings of low extents of protein glycation *in vivo*.[22, 47] Protein glycation may reach it highest extent of modification for long-lived basement membrane proteins of the peritoneal cavity basement membrane for renal failure patients receiving long term treatment with PD fluids containing high concentrations of glucose osmolyte. Since RAGE activation is not limited to these conditions, it is likely that ligands other than highly glycated proteins are important agonists for the RAGE receptor physiologically.

Ligand binding studies of RAGE have often been performed with albumin highly modified with AGEs where competitive binding and deductions from crystallographic data of RAGE suggest interaction is driven by the high negative charge of this ligand[48, 49]. There are doubts, therefore, if such interaction is found *in vivo*. Further studies characterised the binding affinities of major AGE residues and AGE free adducts to RAGE by measuring changes of intrinsic tryptophan fluorescence and high resolution nuclear magnetic resonance (NMR) chemical shifts of peptide backbone of the extracellular domain of RAGE.[50, 51] Herein binding affinities were used to deduce percent RAGE occupancy by AGEs *in vivo*. CML and CEL free adducts did not bind to RAGE; and CML and CEL residues had very low affinities

for RAGE such that predicted receptor occupancies in healthy controls and HD patients *in vivo* are very low; only 3 – 8%. This is contrary to initial findings which involved use of CML-modified albumin prepared by chemical reductive alkylation of albumin.[52] Chemically generated CML-modified albumin may have damaged albumin structurally, producing anomalous aggregates which bound to RAGE. In contrast, MG-H1 and related structural isomers, residues and free adducts, have *ca.* 2000-fold higher affinity for RAGE, suggesting MG-derived hydroimidazolone is recognised specifically[50] – Table 1. Albumin modified minimally by MG containing mainly MG-H1 residues was found previously to bind RAGE.[46] The unexpected finding, however, is that RAGE is always saturated with MG-H1 modified protein in healthy subjects and CKD patients, suggesting that this binding may is non-productive for activation of signal transduction. RAGE was recently found to have a high affinity homophilic binding with K_D of 470 nM mediating cell-cell interaction. Hence, normally much of the cellular RAGE protein pool may not be available for AGE-modified protein binding and competent to activate related signal transduction.[53]

Heparan sulfate-RAGE complexes were found to be essential for signal transduction of RAGE activated by AGE-modified albumin, high mobility group protein 1 (HMGB1) and S100 proteins.[54] Signalling downstream from RAGE-heparan sulfate-activating ligand ternary complex studied to date involved extracellular regulated kinase-1 and -2 and p38 MAP kinase phosphorylations. Erk activation mediates pro-fibrotic responses and extracellular matrix expansion.[55] p38 MAP kinase activation is linked to endothelial permeability, inflammation and renal fibrosis.[56-58] Interplay of heparan sulfate and heparanase in CKD may influence the signalling competence of MG-H1 with RAGE.[59] Down regulation of RAGE expression may have beneficial responses, independent of the activating ligand, by countering the increased expression of CKD.[60] Decreased activity of RAGE is associated with decreased podocyte production of monocyte chemoattractant protein-1 (MCP-1),[61] decreased monocyte recruitment, glomerulosclerosis, extracellular matrix accumulation, albuminuria and decline in renal function.[62-64]

Dicarbonyl proteome

Protein dysfunction and inactivation is produced directly by formation of MG-H1 and similar hydroimidazolone AGEs on functional arginine residues of proteins. This likely makes a major contribute to AGE pathogenesis in CKD because: (i) MG-H1 is the AGE of highest flux of formation in CKD; (ii) MG-H1 formation produces loss of charge and all electrostatic interactions of arginine residue modification, eliminating functional interactions and activities; (iii) arginine residues have a high probability of location in functional domains of proteins (20%); and (iv) MG modification tends to occur on functionally-important arginine residues. Proteins modified by MG and related dicarbonyl metabolites are called collectively the "dicarbonyl proteome". Examples of protein targets of MG glycation are: collagen-4 – preferentially modified by MG at integrin binding sites driving endothelial cell detachment, increased circulating endothelial cells and vascular damage;[65] mitochondrial proteins – leading to increased formation of reactive oxygen species;[66] LDL - inducing pro-atherogenic transformation to small dense LDL driving dyslipidemia;[67] p65 of the NF-kB system - leading to increased expression of RAGE and S100A8, S100A12, and HMGB1 and enhanced and persistent vascular inflammation;[68] and apolipoprotein-A1 - inducing de-stabilisation of HDL, contributing to dyslipidemia.[69] Effects of the dicarbonyl proteomes may be modelled *in vitro* by silencing of Glo1. In endothelial cells this triggered increased expression of collagens-1 and -5, endothelin-1, ICAM-1, VCAM-1 and of MCP-1;[70] and in L6 myoblasts increased collagen-1 and -4.[71] This suggests that dicarbonyl stress is a driver of vascular renal inflammation and renal and muscle fibrosis – considered critical to CKD progression and co-morbidities - cardiovascular disease and muscle wasting.[72, 73] The dicarbonyl proteome may

be characterised by high resolution mass spectrometry of tryptic digests of cell protein extracts.[74] This remains to be applied to renal cells and tissue extracts.

Contribution of food AGEs to clinical AGE exposure and health impairment
There is a high content of AGEs in sugar-rich, thermally processed foods. The clinical impact of dietary-derived AGEs remains uncertain. It may be particularly important in CKD where clearance and excretion of AGEs is impaired. Advance on this has been stymied by lack of experimental evidence on the amount of AGEs absorbed from food. Dietary AGEs have low bioavailability. An approach to resolve these is to exploit the measurement of pyrraline – an AGE found exclusively in food[75, 76] – Figure 3. Urinary excretion of AGE free adducts provides an estimate of total body AGE exposure and urinary exertion of pyrraline reflects absorption of AGEs from food. Correlation of urinary excretion of a particular AGE with urinary exertion of pyrraline reflects a significant contribution of the AGE from food. Linear regression of urinary AGE excretion on urinary exertion of pyrraline and extrapolation to zero pyrraline excretion gives an estimate of the flux of AGE formed endogenously in the body. AGE absorbed from food then equals the total urinary AGE flux minus this deduced endogenous AGE flux.[77] This analysis was performed recently for MG-H1. In healthy overweight and obese subjects, the flux of endogenous formation of MG-H1 at baseline was *ca.* 13 nmol/mg creatinine, representing 68% of total MG-H1 exposure; the mean contribution to total MG-H1 exposure from the diet was 32% but highly variable.[77] Similar studies are now required in CKD patients. The diet is likely often a minor source of MG-H1 exposure.

Several clinical studies with interventions to decrease exposure to dietary AGEs in CKD for improved vascular health have been performed, with often assessment of markers of vascular inflammation.[78, 79] These and other studies were evaluated by meta-analysis for overall assessment of evidence of health benefits.[80] There are difficulties of interpretation as unblinded study designs were used. It was concluded that there is insufficient evidence, at present, of health benefit to recommend dietary AGE restriction in patients with CKD.[80] An advance that was thought would improve studies of this type was direct determination of the proportions of AGEs exposure originating from the diet endogenous origin. This has recently been provided[77] – see above. There is a need for long-term, high-quality randomised controlled trials with large sample size and masking of the AGE intervention to provide more robust evidence on the health impact of dietary AGEs in CKD – also taking advantage of recent advances in improved quantitation of AGEs in food.[81] In preclinical studies, it was found that diabetic mice on a low AGE diet still developed diabetic nephropathy.[82] A recent open label, pilot study found effects of a high AGE diet on intestinal microbiota in renal failure patients receiving PD therapy.[83]

AGEs formed endogenously in proteins are likely the most damaging to physiological function. Dietary AGEs are absorbed as free adducts after digestion or as peptides which are hydrolysed by peptidases to AGE free adducts after absorption.[22] To date, there is no evidence that AGE free adducts from food may be incorporated into endogenous proteins but they may equilibrate with pools of AGE free adducts in plasma and tissues. Endogenous flux of formation of MG-H1 and other AGEs may be improved AGE-related clinical biomarkers to assess association with progression of CKD and risk of associated co-morbidities.

AGE-related therapeutics - Glyoxalase 1 inducers
Glycation by dicarbonyls is non-oxidative and so it is insensitive to antioxidants. It requires a new type of pharmacological agent for therapy. Experimental agents have been developed to scavenge reactive dicarbonyls and an existing therapeutic agent for patients with type 2 diabetes (T2DM), metformin, also reacts with MG. These provide ineffective removal of MG

compared to *in situ* activity of Glo1 – Table 2. Decrease of MG levels in patients with T2DM treated with metformin[84] is likely mainly achieved through increase in glycaemic control.[85] Therapeutic agents that induce Glo1 expression may be better because: (i) Glo1 metabolises >97% of MG formed in human metabolism;[10] (ii) they correct decreased renal Glo1 activity which is a common characteristic of animal models of DKD;[86-88] and (iii) pre-clinical studies showing decreased Glo1 expression potentiates and overexpression of Glo1 prevents the development of diabetic nephropathy.[7, 12, 89]

Small molecule inducers of Glo1 expression or "Glo1 inducers" may be developed as activators of Nrf2, exploiting a regulatory antioxidant response element (ARE) in the GLO1 gene. Glo1 inducers decreased cellular and extracellular concentrations of MG, MG-derived AGE formation and related functional impairment - such as endothelial attachment to collagen-4.[90] We screened Glo1 inducers with a functional assay based on GLO1-ARE linked expression.[90] The best Glo1 inducer was a combination of *trans*-resveratrol (tRES) and hesperetin (HESP), tRES-HESP.[77]

tRES-HESP combination was evaluated in Phase 1 clinical trial in overweight and obese subjects to establish safety and target pharmacology. Functional assessments of metabolic health were also included - Phase 2A trial for metabolic health benefit in obesity. The study was a randomized, double blind, placebo-controlled crossover study in 29 subjects. Dosing was by oral capsule, once daily, containing tRES-HESP or placebo. Dosing periods were 8 weeks with 6 weeks washout between in the crossover period. Urinary excretion of tRES and HESP metabolites was increased >2000-fold and >100 fold, respectively, compared to placebo. Clinical safety indicators were normal at study entry and remained unchanged throughout the placebo and tRES-HESP treatment periods. tRES-HESP treatment produced a 22% increase in Glo1 activity of peripheral blood mononuclear cells (PBMCs) of all subjects, compared to placebo. The increase was 30% in the obese sub-group (subjects with BMI $\geq$ 30 kg/m^2). Concomitant with increased Glo1 activity, there was a 37% decrease in plasma MG post-supplementation with tRES-HESP but not with placebo. The flux of endogenously-generated MG-H1 adducts was *ca.* 13 nmol/mg creatinine at baseline and decreased by 14% with tRES-HESP treatment but not with placebo.[77]

tRES-HESP treatment produced a profound effect on glucose metabolism. Insulin resistance was corrected to levels typical of lean subjects with normal insulin sensitivity; dysglycaemia was improved - fasting plasma glucose decreased 5% and 2-h area-under-the-curve plasma glucose in an oral glucose tolerance test decreased 8%. This suggests tRES-HESP may be highly beneficial for treatment of insulin resistance in CKD. Other changes were: 3% increase in eGFR and 9% decrease in plasma urea with tRES-HESP. The study participants had stages G1 and G2 CKD with renal function assessments were made at only once at study visits and so these responses require validation in further studies and advanced stages of CKD.

There was also a profound effect of tRES-HESP on inflammatory gene expression, assessed in PBMCs. In all subjects there was a 30% decrease of prostaglandin-endoperoxide synthase 2 (PTGS2 or COX2) and 39% decrease of interleukin-8 (IL-8). In the highly-overweight subgroup there was also marked decreases of RAGE (37%) and MCP-1 (49%). Treatment with placebo produced no change. Inhibition of RAGE and MCP-1 signalling are targets for drug development in CKD.

The health beneficial effects of tRES-HESP have not been achieved by these compounds individually, even at markedly higher doses.[91, 92] The likely explanation for this is synergistic pharmacological effects in activation of Nrf2[77] and improved bioavailability of tRES through inhibition of intestinal glucuronosyltransferases by HESP.[93] If confirmed, this circumvention of bioavailability problems of tRES may be a major advance to translating promise of health benefits of tRES for clinical applications – Figure 5. In experimental models of DKD, tRES

and hesperidin – a glycoside derivative of HESP, decreased albuminuria, glomerular matrix expansion, inflammation and renal function decline, albeit at doses that are not translatable clinically.[94, 95]

The Glo1 inducer appears to be particularly appropriate and timely for treatment of CKD, addressing multiple targets of cell and tissue dysfunction. It may correct renal extracellular matrix disposition and dysfunction, fibrosis and inflammation – allowing for re-engagement of podocyte food processes and re-establishment of normal glomerular endothelial cell, mesangial cell and fibular cell function to re-instate the glomerular filtration barrier and improve GFR – Figure 4. Some of the benefits of tRES-HESP may be due to concurrent induction of increased expression of other protective ARE-linked genes - including protection against other dicarbonyls since expression of AKRs was also induced.[77]

Concluding remarks

It is likely that dicarbonyl stress and increased formation of MG-H1 is a key contributory factor in the development of CKD for which down regulation of renal Glo1 appears to be a key driver. Correction of this by Glo1 inducers offers a new strategy for treatment and measurement of flux of MG-H1 new companion diagnostics to guide their use in precision medicine. New features of AGE research in CKD are summarised in Table 3.

ACKNOWLEDGEMENTS

We thank our research team and collaborators for their efforts on MG and Glo1-related research.

DISCLOSURE

The authors are inventors on a patent of the Glo1 inducer tRES-HESP and related formulations.

REFERENCES

1. Thornalley PJ, Rabbani N. Detection of oxidized and glycated proteins in clinical samples using mass spectrometry - A user's perspective. *Biochim Biophys Acta* 2014; **1840:** 818-829.
2. Thornalley PJ, Waris S, Fleming T*, et al.* Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance. *Nucleic Acids Res* 2010; **38:** 5432-5442.
3. Requena JR, Ahmed MU, Fountain CW*, et al.* Carboxymethylethanolamine, a biomarker of phospholipid modification during the Maillard reaction in vivo *J Biol Chem* 1997; **272:** 17473-17479.
4. Waris S, Winklhofer-Roob BM, Roob JM*, et al.* Increased DNA Dicarbonyl Glycation and Oxidation Markers in Patients with Type 2 Diabetes and Link to Diabetic Nephropathy. *J Diabetes Res* 2015; **2015:** 10.
5. Rabbani N, Thornalley PJ. Dicarbonyls (Glyoxal, Methylglyoxal, and 3-Deoxyglucosone). *Uremic Toxins*. John Wiley & Sons, Inc., 2012, pp pp. 177-192.
6. Nishimura C, Furue M, Ito T*, et al.* Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. *Biochem Pharmac* 1993; **46:** 21-28.
7. Giacco F, Du X, D'Agati VD*, et al.* Knockdown of Glyoxalase 1 Mimics Diabetic Nephropathy in Nondiabetic Mice. *Diabetes* 2014; **63:** 291-299.
8. Rabbani N, Sebekova K, Sebekova K, Jr.*, et al.* Protein glycation, oxidation and nitration free adduct accumulation after bilateral nephrectomy and ureteral ligation. *Kidney Internat* 2007; **72:** 1113-1121.
9. Ficek J, Wyskida K, Ficek R*, et al.* Relationship between plasma levels of zonulin, bacterial lipopolysaccharides, d-lactate and markers of inflammation in haemodialysis patients. *Internat UrolNephrol* 2017; **49:** 717-725.
10. Rabbani N, Xue M, Thornalley PJ. Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments. *Clin Sci* 2016; **130:** 1677–1696.
11. Ikeda Y, Inagi R, Miyata T*, et al.* Glyoxalase I Retards Renal Senescence. *Amer J Pathol* 2011; **179:** 2810-2821.
12. Brouwers O, Niessen PMG, Miyata T*, et al.* Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. *Diabetologia* 2014; **57:** 224-235.
13. Agalou S, Ahmed N, Babaei-Jadidi R*, et al.* Profound mishandling of protein glycation degradation products in uremia and dialysis. *J Amer Soc Nephrol* 2005; **16:** 1471-1485.
14. Schwedler SB, Metzger T, Schinzel R*, et al.* Advanced glycation end products and mortality in hemodialysis patients. *Kidney Internat* 2002; **62:** 301-310.
15. Wagner Z, Molnar M, Molnar GA*, et al.* Serum carboxymethyllysine predicts mortality in hemodialysis patients. *Amer J Kidney Dis* 2006; **47:** 294-300.
16. Monnier VM, Sell DR, Strauch C*, et al.* The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. *J Diabetes Compl* 2013; **27:** 141-149.
17. Ahmed MU, Thorpe SR, Baynes JW. Identification of Nε-carboxymethyl-lysine as a degradation product of fructoselysine in glycated protein. *J Biol Chem* 1986; **261:** 4889-4894.
18. Biemel KM, Friedl DA, Lederer MO. Identification and quantification of major Maillard cross-links in human serum albumin and lens protein - Evidence for glucosepane as the dominant compound. *J Biol Chem* 2002; **277:** 24907-24915.

19. Wang F, Zhao Y, Niu Y, *et al.* Activated glucose-6-phosphate dehydrogenase is associated with insulin resistance by upregulating pentose and pentosidine in diet-induced obesity of rats. *HormMetab Res* 2012; **44:** 938-942.

20. Rabbani N, AntonySunil A, Rossing K, *et al.* Effect of Irbesartan treatment on plasma and urinary protein glycation, oxidation and nitration markers in patients with type 2 diabetes and microalbuminuria. *Amino Acids* 2011; **42:** 1627-1639.

21. Masania J, Malczewska-Malec M, Razny U, *et al.* Dicarbonyl stress in clinical obesity. *Glycoconjugate J* 2016; **33:** 581-589.

22. Ahmed N, Thornalley PJ, Luthen R, *et al.* Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. *J Hepatol* 2004; **41:** 913-919.

23. Semba RD, Fink JC, Sun K, *et al.* Serum Carboxymethyl-Lysine, a Dominant Advanced Glycation End Product, Is Associated With Chronic Kidney Disease: The Baltimore Longitudinal Study of Aging. *J Renal Nutrit* 2010; **20:** 74-81.

24. Zhang X, Frischmann M, Kientsch-Engel R, *et al.* Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. *Clin Chem Lab Med* 2005; **43:** 503.

25. Lieuw AF, van Hinsbergh VWM, Teerlink T, *et al.* Increased levels of Nî-(carboxymethyl)lysine and Nî-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. *Nephrol Dial Transplant* 2004; **19:** 631-636.

26. Machowska A, Sun J, Qureshi AR, *et al.* Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease. *PLOS ONE* 2016; **11:** e0163826.

27. Genuth S, Sun W, Cleary P, *et al.* Skin Advanced Glycation Endproducts (AGEs) Glucosepane and Methylglyoxal Hydroimidazolone are Independently Associated with Long-term Microvascular Complication Progression of Type I diabetes. *Diabetes* 2015; **64:** 266-278.

28. Klein R, Horak K, Lee KE, *et al.* The Relationship of Serum Soluble Receptor for Advanced Glycation End Products (sRAGE) and Carboxymethyl Lysine (CML) to the Incidence of Diabetic Nephropathy in Persons With Type 1 Diabetes. *Diabetes Care* 2017.

29. Beisswenger PJ, Howell SK, Russell GB, *et al.* Early Progression of Diabetic Nephropathy Correlates With Methylglyoxal-Derived Advanced Glycation End Products. *Diabetes Care* 2013; **36:** 3234-3239.

30. Roberts MA, Thomas MC, Fernando D, *et al.* Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. *Nephrol Dial Transplant* 2006; **21:** 1611-1617.

31. Meerwaldt R, Graaff R, Oomen PHN, *et al.* Simple non-invasive assessment of advanced glycation endproduct accumulation. *Diabetologia* 2004; **47:** 1324-1330.

32. Na RH, Stender IM, Ma LX, *et al.* Autofluorescence spectrum of skin: component bands and body site variations. *Skin Res Technol* 2000; **6:** 112-117.

33. Masters BR, So PTC. Confocal microscopy and multi-photon excitation microscopy of human skin in vivo. *Opt Express* 2001; **8:** 2-10.

34. Tanaka K, Nakayama M, Kanno M, *et al.* Skin Autofluorescence Is Associated with the Progression of Chronic Kidney Disease: A Prospective Observational Study. *PLOS ONE* 2013; **8:** e83799.

35. Meerwaldt R, Hartog JWL, Graaff R, *et al.* Skin Autofluorescence, a Measure of Cumulative Metabolic Stress and Advanced Glycation End Products, Predicts Mortality in Hemodialysis Patients. *J Amer Soc Nephrol* 2005; **16:** 3687-3693.

36. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. *Cell Molec Biol* 1998; **44:** 1013-1023.

37. Thornalley PJ. Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE) - an introduction. *Molec Nutritand Food Res* 2007; **51:** 1107-1110.

38. Yamamoto Y, Kato I, Doi T, *et al.* Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. *J Clin Invest* 2001; **108:** 261-268.

39. Sourris KC, Morley AL, Koitka A, *et al.* Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. *Diabetologia* 2010; **53:** 2442-2451.

40. Hou FF, Ren H, Owen WF, *et al.* Enhanced Expression of Receptor for Advanced Glycation End Products in Chronic Kidney Disease. *J Amer Soc Nephrol* 2004; **15:** 1889-1896.

41. Thornalley PJ, Argirova M, Ahmed N, *et al.* Mass spectrometric monitoring of albumin in uraemia. *Kidney Internat* 2000; **58:** 2228-2234.

42. Westwood ME, Thornalley PJ. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. *J Prot Chem* 1995; **14:** 359-372.

43. Matsumoto K, Sano K, Nagai R, *et al.* Endocytic uptake of advanced glycation end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor distinct from the macrophage scavenger receptor class A. *Biochem J* 2000; **352:** 233-240.

44. Degenhardt TP, Grass L, Reddy S, *et al.* The serum concentration of the advanced glycation end-product Nî-(carboxymethyl)lysine is increased in uremia. *Kidney Internat* 1997; **52:** 1064-1067.

45. Buetler TM, Leclerc E, Baumeyer A, *et al.* N-epsilon-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. *Molec Nutrit & Food Res* 2008; **52:** 370-378.

46. Ng R, Argirov OK, Ahmed N, *et al.* Human serum albumin minimally modified by methylglyoxal binds to human mononuclear leukocytes via the RAGE receptor and is displaced by N-carboxymethyl-lysine and hydroimidazolone AGE epitopes. *Internat Congr Ser* 2002; **1245:** 77-81.

47. Rabbani N, Thornalley PJ. Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. *Nature Protocols* 2014; **9:** 1969-1979.

48. Osawa M, Yamamoto Y, Munesue S, *et al.* De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. *Biochim Biophys Acta* 2007; **1770:** 1468-1474.

49. Park H, Boyington JC. The 1.5 Å Crystal Structure of Human Receptor for Advanced Glycation Endproducts (RAGE) Ectodomains Reveals Unique Features Determining Ligand Binding. *J Biol Chem* 2010; **285:** 40762-40770.

50. Xue J, Ray R, Singer D, *et al.* The Receptor for Advanced Glycation End Products (RAGE) Specifically Recognizes Methylglyoxal-Derived AGEs. *Biochemistry* 2014; **53:** 3327-3335.

51. Xue J, Rai V, Singer D, *et al.* Advanced Glycation End Product Recognition by the Receptor for AGEs. *Structure* 2011; **19:** 722-732.

52. Kislinger T, Fu C, Huber B, *et al.* Nε-(Carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. *J Biol Chem* 1999; **274:** 31740-31749.

53. Sessa L, Gatti E, Zeni F, *et al.* The Receptor for Advanced Glycation End-Products (RAGE) Is Only Present in Mammals, and Belongs to a Family of Cell Adhesion Molecules (CAMs). *PLoS ONE* 2014; **9:** e86903.

54. Xu D, Young JH, Krahn JM, *et al.* Stable RAGE-Heparan Sulfate Complexes Are Essential for Signal Transduction. *ACS Chem Biol* 2013; **8:** 1611-1620.

55. Feliers D, Kasinath BS. Erk in Kidney Diseases. *J Signal Trans* 2011; **2011:** 8.

56. Borbiev T, Birukova A, Liu F, *et al.* p38 MAP kinase-dependent regulation of endothelial cell permeability. *Amer J Physiol - Lung Cell Molec Physiol* 2004; **287:** L911-L918.

57. Yang Y, Kim SC, Yu T, *et al.* Functional Roles of p38 Mitogen-Activated Protein Kinase in Macrophage-Mediated Inflammatory Responses. *Mediators of Inflammation* 2014; **2014:** 352371.

58. Stambe C, Atkins RC, Tesch GH, *et al.* The Role of p38α Mitogen-Activated Protein Kinase Activation in Renal Fibrosis. *J Amer Soc Nephrol* 2004; **15:** 370-379.

59. Rabelink TJ, van den Berg BM, Garsen M, *et al.* Heparanase: roles in cell survival, extracellular matrix remodelling and the development of kidney disease. *Nat Rev Nephrol* 2017; **13:** 201-212.

60. Abel M, Ritthaler U, Zhang Y, *et al.* Expression of receptors for advanced glycosylated end-products in renal disease. *Nephrol Dial Transplant* 1995; **10:** 1662-1667.

61. Gu LY, Hagiwara S, Fan QL, *et al.* Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. *Nephrol Dial Transplant* 2006; **21:** 299-313.

62. Wendt TM, Tanji N, Guo J, *et al.* RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. *Amer J Pathol* 2003; **162:** 1123-1137.

63. Chow FY, Nikolic-Paterson DJ, Ozols E, *et al.* Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. *Kidney Internat* 2006; **69:** 73-80.

64. Che J, Okigaki M, Takahashi T, *et al.* Endothelial FGF receptor signaling accelerates atherosclerosis. *Amer J Physiol- Heart Circ Physiol* 2011; **300:** H154-H161.

65. Dobler D, Ahmed N, Song LJ, *et al.* Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. *Diabetes* 2006; **55:** 1961-1969.

66. Morcos M, Du X, Pfisterer F, *et al.* Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in *Caenorhabditis elegans*. *Aging Cell* 2008; **7:** 260-269.

67. Thornalley PJ, Rabbani N. Protein damage in diabetes and uremia - identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiological effect. *Free Radical Res* 2010; **45:** 89-100.

68. Yao D, Brownlee M. Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of RAGE and RAGE Ligands. *Diabetes* 2009; **59:** 249-255.

69. Godfrey L, Yamada-Fowler N, Smith JA, *et al.* Arginine-directed glycation and decreased HDL plasma concentration and functionality. *Nutrit Diabetes* 2014; **4:** e134.

70. Stratmann B, Engelbrecht B, Espelage BC, *et al.* Glyoxalase 1-knockdown in human aortic endothelial cells – effect on the proteome and endothelial function estimates. *Sci Rep* 2016; **6:** 37737.

71. Stratmann B, Goldstein B, Thornalley P, *et al.* Intracellular Accumulation of Methylglyoxal by Glyoxalase 1 Knock Down Alters Collagen Homoeostasis in L6 Myoblasts. *Internat J Molec Sci* 2017; **18:** 480.

72. Boor P, Šebeková K, Ostendorf T, *et al.* Treatment targets in renal fibrosis. *Nephrol Dial Transplant* 2007; **22:** 3391-3407.

73. Stenvinkel P, Carrero JJ, von Walden F, *et al.* Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. *Nephrol Dial Transplant* 2016; **31:** 1070-1077.

74. Rabbani N, Ashour A, Thornalley PJ. Mass spectrometric determination of early and advanced glycation in biology. *Glycoconjugate J* 2016; **33:** 553-568.

75. Foerster A, Henle T. Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): studies on the urinary excretion of pyrraline. *Biochem Soc Trans* 2003; **31:** 1383-1385.

76. Hohmann C, Liehr K, Henning C, *et al.* Detection of Free Advanced Glycation End Products in Vivo during Hemodialysis. *J Agric Food Chem* 2017; **65:** 930-937.

77. Xue M, Weickert MO, Qureshi S, *et al.* Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation *Diabetes* 2016; **65:** 2282-2294.

78. Vlassara H, Cai W, Goodman S, *et al.* Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. *J Clin Endocrinol Metab* 2009; **94:** 4483-4491.

79. Harcourt BE, Sourris KC, Coughlan MT, *et al.* Targeted reduction of advanced glycation improves renal function in obesity. *Kidney Internat* 2011; **80:** 190-198.

80. Kellow NJ, Coughlan MT, Savige GS, *et al.* Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial. *BMC endocrine disorders* 2014; **14:** 55.

81. Scheijen JLJM, Clevers E, Engelen L, *et al.* Analysis of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: Presentation of a dietary AGE database. *Food Chem* 2016; **190:** 1145-1150.

82. Thallas-Bonke V, Coughlan MT, Tan ALY, *et al.* Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. *Nephrology* 2013; **18:** 47-56.

83. Yacoub R, Nugent M, Cai W, *et al.* Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial. *PLOS ONE* 2017; **12:** e0184789.

84. Beisswenger PJ, Howell SK, Touchette A, *et al.* Metformin reduces systemic methylglyoxal levels in type 2 diabetes. *Diabetes* 1999; **48:** 198-202.

85. Battah S, Ahmed N, Thornalley PJ. Kinetics and mechanism of the reaction of metformin with methylglyoxal. *Internat Congr Ser* 2002; **1245:** 355-356.

86. Bierhaus A, Fleming T, Stoyanov S, *et al.* Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. *Nature Med* 2012; **18:** 926-933.

87. Barati MT, Merchant ML, Kain AB, *et al.* Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice. *Amer J Physiol - Renal Physiol* 2007; **293:** F1157-F1165.

88. Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2/Keap1 signaling. *Biochim Biophys Acta* 2011; **1812:** 719-731.

89. Geoffrion M, Du X, Irshad Z*, et al.* Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. *Physiological Reports* 2014; **2:** e12043.

90. Xue M, Rabbani N, Momiji H*, et al.* Transcriptional control of glyoxalase 1 by Nrf2 provides a stress responsive defence against dicarbonyl glycation. *Biochem J* 2012; **443:** 213-222.

91. Liu K, Zhou R, Wang B*, et al.* Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. *Amer J Clin Nutrit* 2014; **99:** 1510-1519.

92. Rizza S, Muniyappa R, Iantorno M*, et al.* Citrus Polyphenol Hesperidin Stimulates Production of Nitric Oxide in Endothelial Cells while Improving Endothelial Function and Reducing Inflammatory Markers in Patients with Metabolic Syndrome. *J Clin Endocrinol & Metab* 2011; **96:** E782-E792.

93. Silberberg M, Morand C, Mathevon T*, et al.* The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. *Eur J Nutrit* 2006; **45:** 88-96.

94. Kim MY, Lim JH, Youn HH*, et al.* Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK–SIRT1–PGC1α axis in db/db mice. *Diabetologia* 2013; **56:** 204-217.

95. Jain DP, Somani RS. Hesperidin ameliorates streptozotocin and high fat diet induced diabetic nephropathy in rats. *J Exp Integr Med* 2014; **4:** 261-267.

96. Ruggiero-Lopez D, Lecomte M, Moinet G*, et al.* Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. *Biochem Pharmacol* 1999; **58:** 1765-1773.

97. Kinsky OR, Hargraves TL, Anumol T*, et al.* Metformin Scavenges Methylglyoxal To Form a Novel Imidazolinone Metabolite in Humans. *Chem Res Toxicol* 2016.

98. Thornalley PJ, Yurek-George A, Argirov OK. Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoaldehydes, glyoxal, methylglyoxal and 3-deoxyglucosone under physiological conditions *Biochem Pharmacol* 2000; **60:** 55-65.

99. Agalou S, Karachalias N, Dawnay AB*, et al.* Reaction kinetics of the scavenging of alpha-oxoaldehydes by aminoguanidine under physiological conditions. *Maillard Reaction in Food Chemistry and Medical Science: Update for the Postgenomic Era* 2002; **1245:** 513-515.

100. Nyengaard JR, Chang K, Berhorst S*, et al.* Discordant effect of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. *Diabetes* 1997; **46:** 94-106.

101. Freedman BI, Wuerth JP, Cartwright K*, et al.* Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). *Controlled Clinical Trials* 1999; **20:** 493-510.

102. Oturai PS, Rasch R, Haselager E*, et al.* Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats. *APMIS* 1996; **104:** 259-264.

103. Kim T, Spiegel DA. Unique reactivity of N-phenacyl-derived thiazolium salts toward α-dicarbonyl compounds. *Rejuvenation Res* 2012; **16:** 43-50.

104. Thornalley PJ, Minhas HS. Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. *Biochem Pharmacol* 1999; **57:** 303-307.

105. Price DL, Rhett PM, Thorpe SR*, et al.* Chelating activity of advanced glycation end-product inhibitors. *J Biol Chem* 2001; **276:** 48967-48972.

106. Thallas-Bonke V, Lindschau C, Rizkalla B, *et al.* Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C-{alpha}-Dependent Pathway. *Diabetes* 2004; **53:** 2921-2930.

107. Padayatti PS, Ng AS, Uchida K, *et al.* Argpyrimidine, a blue fluorophore in human lens proteins: high levels in brunescent cataractous lenses. *Invest Ophthalmol Vis Sci* 2001; **42:** 1299-1304.

108. Degenhardt TP, Alderson NL, Arrington DD, *et al.* Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. *Kidney Internat* 2002; **61:** 939-950.

109. Lewis EJ, Greene T, Spitalewiz S, *et al.* Pyridorin in Type 2 Diabetic Nephropathy. *J Amer Soc Nephrol* 2012; **23:** 131-136.

110. Lo TWC, Selwood T, Thornalley PJ. Reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. *Biochem Pharmacol* 1994; **48:** 1865-1870.

111. Brings S, Fleming T, De Buhr S, *et al.* A scavenger peptide prevents methylglyoxal induced pain in mice. *Biochim Biophys Acta* 2017; **1863:** 654-662.

112. Chen Y, Akirav EM, Chen W, *et al.* RAGE Ligation Affects T Cell Activation and Controls T Cell Differentiation. *J Immunol* 2008; **181:** 4272-4278.

113. Bell J, Mancuso J, Kupiec J, *et al.* Results of a randomized trial to evaluate a novel RAGE inhibitor in patients with diabetic nephropathy. *Diabetes* 2011; **60:** Suppl. 1, A262.

Table 1 │ Binding affinities and predicted *in vivo* occupancy of RAGE with AGE residues and AGE free adducts.

Ligand	K_D (µM)	[AGE], healthy control and stage 5 CKD (µM)	Receptor occupancy in healthy subjects (%)	Receptor occupancy in HD patients (%)
CML residue	87	2.3 and 8.0	2.6	8.4
CEL residue	93	1.1 and 2.6	1.2	2.7
MG-H1 residue	0.040	12.8 and 22.0	99.7	99.8
MG-H1 free adduct	0.040	0.12 and 4.8	54.9	99.0
G-H1 free adduct	0.043	0.04 and 0.26	21.6	32.7
RAGE	0.47	0.13 and 0.73	18.4	45.7

Assumptions: RAGE protein copy number in human monocytes *in vivo* was 37,000 and 208,000 per cell in healthy subjects and HD patients, respectively,[40] equivalent to a concentration of *ca.* 130 and 730 nM. K_D and AGE concentration values as given.[13, 50, 51] Receptor occupancy was determined by deducing the equilibrium position of the binding equation AGE + RAGE = AGE-RAGE.

Table 2 │ Experimental therapeutic agents to counter dicarbonyl stress.

Agents	Mechanism of action	Advantages/advantages
Glo1 inducer	Increased expression of Glo1 (high efficiency catalytic removal of MG and glyoxal)	Corrects deficiency of Glo1 in the kidney and elsewhere driving dicarbonyl stress-induced mechanisms of CKD.[88] Limited to effects on Glo1 substrates. Induction occurs rapidly within a few hours and is relatively long lasting; Glo1 half-life is 2 – 3 days.[77, 90]
Metformin	Dicarbonyl scavenger (stoichiometric removal)	Known pharmacological and safety profile. Reacts with MG to form mainly hydroimidazolone-like and also triazepinone adducts but they are quantitatively minor compared to the flux of MG formation.[96, 97]
Aminoguanidine (Pimagedine)	Dicarbonyl scavenger (stoichiometric removal)	Aminoguanidine reacts with MG and other dicarbonyls to form 3-amino-1,2,4-triazine derivatives.[98, 99] At peak concentration, aminoguanidine is an effective MG scavenger in plasma but not inside cells where it is expected to compete ineffectively with Glo1 but this is short-lived; plasma half-life is *ca.* 1.4 h. [100] In clinical trial adverse effects were gastrointestinal disturbance, abnormal liver function tests, flu-like symptoms and a rare vasculitis.[101] Clinical therapeutic development was questioned further when kidney tumours were found in aminoguanidine-treated diabetic rats.[102]
Phenacylthiazolium bromide (PTB) and related derivatives e.g. Alagebrium	Dicarbonyl scavenger (stoichiometric removal)	PTB is an efficient scavenger of MG*; ca.* 6-fold more effective than aminoguanidine under physiological conditions.[98, 103] Unstable under physiological conditions, degrading by hydrolysis with a half-life of 44 min.[104] An effective MG scavenger in plasma for a short period but not inside cells where it is expected to compete ineffectively with Glo1. Alagebrium shows similar properties.[105] It improved albuminuria in experimental diabetic nephropathy.[106] A Phase 2 clinical trial in patients with type 1 diabetes and microalbuminuria was terminated early for financial reasons (identifier NCT00557518, clinicaltrials.gov).
Pyridoxamine	Dicarbonyl scavenger (stoichiometric removal)	Well tolerated. Relatively low reactivity with dicarbonyls.[107] May function through other, non-AGE mechanisms (supplementation of vitamin B_6 metabolism).[108] Judged to have failed in phase 2 clinical trial for treatment of diabetic nephropathy.[109]

Table 2 │ Experimental therapeutic agents to counter dicarbonyl stress (cont'd).

Agents	Mechanism of action	Advantages/advantages
Arginine and arginine-rich peptides	Dicarbonyl scavenger (stoichiometric removal)	Well tolerated but poor scavenger activity: median effective concentration of arginine in an *ex vivo* model of plasma protein glycation was 23 mM.[110] These agents are competing with high endogenous cellular and extracellular arginine residue concentrations; *ca.* 20 mM and 80 mM, respectively. Improved MG scavenging was found with arg-arg and arg-lys residue containing peptides.[86, 111]
TTP488 (PF-04494700)	RAGE inhibitor	May block RAGE signalling.[112] It was evaluated in Phase 2 clinical trial for DKD (6 month treatment, 110 patients). It failed to show effect on urinary albumin-creatinine ratio, eGFR or potential markers of RAGE inhibition.[113]

Table 3 │ New features of AGEs in CKD.

Feature	Description	Key evidence	Reference
Dicarbonyl stress	Dicarbonyl stress is a driver of CKD development which is exacerbated as CKD progresses.	Glo1 silencing in mice imposes a nephropathy phenotype. Experimental and clinical advanced CKD exhibit dicarbonyl stress.	[5, 7, 8]
MG accumulation is of endogenous origin	MG accumulation is driven by down regulation of Glo1 in CKD. Endogenous flux of MG formation far exceeds MG of exogenous origin	Expression and activity of Glo1 is down regulated in experimental CKD. D-Lactate concentration is not increased in CKD.	[9, 10]
MG-H1 is a major challenge to proteostasis in CKD	MG-H1 formation impairs protein function and increased in CKD	Dicarbonyl proteome and flux of MG-H1 increased 9-fold in CKD; 4 – 713 fold higher flux that other AGEs.	[13, 67]
AGE/RAGE interaction	Functional activity of AGEs with RAGE is uncertain	CML and CEL residues have too low affinities to bind RAGE *in vivo*; MG-H1 binds RAGE but binding is always saturated	[13, 50, 51]
Dietary AGEs	The amount of AGEs absorbed from the diet may be deduced from urinary AGE and pyrraline fluxes.	Regression of urinary MG-H1 excretion on urinary pyrraline excretion.	[77]
Glo1 inducer therapeutics	Small molecule inducers of Glo1 expression to counter down regulation of renal Glo1 in CKD.	tRES-HESP combination evaluated in Phase 1/Phase 2A (obesity) clinical trial.	[77]

FIGURE LEGENDS

Figure 1 | Major AGEs in chronic kidney disease.

Figure 2 | The glyoxalase system. Schematic of the glyoxalase metabolic pathway.[10]

Figure 3 | Pyrraline – an AGE exclusively of dietary origin.

Figure 4 | Expected mechanism of action of glyoxalase 1 inducers in chronic kidney disease. Evidence form studies of Glo1 functional genomics and Glo1 overexpression, Glo1 inhibitor and MG treatment of renal cells *in vitro*. Abbreviations: SELE, E-selectin; VCAM-1, vascular cell adhesion molecule-1; Tie2, tyrosine-protein kinase cell-surface receptor for angiopoietin-1, angiopoietin-2 and angiopoietin-4; VEGF, vascular endothelial growth factor; TGFbeta, transforming growth factor-beta.

Figure 5 | Circumventing the problem of low bioavailability of *trans*-resveratrol Impairment of glucuronidation of *trans*-resveratrol and hesperetin in the small intestine by co-administration at pharmaceutical doses. Comparison of the demands on glucuronidation in the intestinal epithelium when tRES alone or in combination with HESP are administered. Abbreviations: HESP-3'-O-G, hesperetin-3'-O-glucuronide; HESP-7-O-G, hesperetin-7-O-glucuronide; tRES-3-O-G, trans-resveratrol-3-O-glucuronide; tRES-4'-O-G, trans-resveratrol-4'-O-glucuronide.

Hydroimidazolone (MG-H1)   **Nε-carboxymethyl-lysine (CML)**   **Glucosepane**

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5